Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.
about
Treatment for lupus nephritisLupus Nephritis in Asia: Clinical Features and ManagementUnmet medical needs in systemic lupus erythematosusLong-term data on tacrolimus treatment in lupus nephritis.The role of neutrophils and NETosis in autoimmune and renal diseases.Recent clinical trials in lupus nephritis.Systemic lupus erythematosus: review of synthetic drugs.Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis.The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.TAC-TIC use of tacrolimus-based regimens in lupus nephritis.Treatment of proliferative lupus nephritis: a slowly changing landscape.Clearing the complexity: immune complexes and their treatment in lupus nephritis.Recent advances in the treatment of lupus nephritis.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.Recent progress in the treatment of lupus nephritis.NFAT gene family in inflammation and cancer.Overview of lupus nephritis management guidelines and perspective from Asia.Treatment of young patients with lupus nephritis using calcineurin inhibitors.Overview of lupus nephritis management guidelines and perspective from Asia.Treatment of severe lupus nephritis: the new horizon.Pharmacokinetic modeling of therapies for systemic lupus erythematosus.The safety of pharmacological treatment options for lupus nephritis.Current and Emerging Therapies for Lupus Nephritis.Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria.Treatment Algorithms in Systemic Lupus Erythematosus.[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis].Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A.[Established medications : new areas of application].Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.Systematic Review and the External Validity of Randomized Controlled Trials in Lupus Nephritis.Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis.
P2860
Q24202572-BA3ECE35-9856-4D60-B572-8D79A724DFFEQ26740487-3F9EA082-6016-4F31-A547-3C1AC2189727Q27005906-366998EA-F647-40D3-80DD-EB283430ED96Q30835209-89560DC6-46F5-425C-83AE-5F84C5B8DCA1Q33904653-B6E369D7-8A6D-4499-95E9-9D1F346EEB5BQ33924437-418996B1-EF48-42E8-9122-454F0F44CC30Q34498515-315232A2-CDA5-4146-BDD9-FA760A33AA74Q35187502-B910ADB8-6805-4DAB-B880-FB17CC102290Q35897121-FBF4CD7D-F3F4-43DC-A078-226B41B8752BQ37587317-43D5A8E0-FB6D-49A3-BACD-5BF6F925DE9CQ37822658-1CF1704F-25A5-4A97-8BC4-10A611ED7135Q37892917-362C8545-B133-45A3-A43D-4CE279AFC948Q37953243-14B02263-38EC-4C89-BE4B-75CA240C69D5Q37954539-FD11DE3C-2CE4-4B41-806B-02E7CED8F18AQ37960525-2AE31C62-3303-48EE-9B88-C00EC82F351EQ38010014-F087A640-4E53-46C1-B300-227441CF1363Q38040813-5236CC81-9867-434D-8918-BDC51013A285Q38123242-4621DDF6-2F1F-4EA4-B574-938E472C6468Q38156915-11ACE9B5-C7B1-4F2C-B16F-5EECC74558ABQ38175076-EBA9BA1F-4586-4085-AC11-556009BBF833Q38271125-CD54A4DB-D16C-45A8-8F6E-E915BE65C58CQ38542910-DA74FC54-DFDA-4133-BD14-90163071E3B0Q38829637-BE1C07FD-27F3-43E7-832A-75A330F9C335Q38855495-A69CDE59-01F2-4AC1-90B4-F8C15F3001EDQ38897055-B446E0B6-EF80-4623-8F50-07A10D9E2A24Q38925320-231FBFF3-CCD7-45C4-989C-CA43746442BFQ39425959-855C1A2B-77A7-4AFB-81A4-0C3F60AEB7B6Q39425964-21EE331F-92C9-4E04-83B3-E52016B99DDAQ40049550-7078CD63-1913-44BA-8D6D-13E16933271BQ41207949-BE8B7108-4BE1-4905-AAAA-4C382C591D31Q41540102-50D97475-2EFD-4168-9289-A2D4A6C0B52CQ43486705-2ED75BEA-8A4F-4C01-9F07-E15EE59F185DQ44480906-9C4E3D27-6D2E-4007-8419-C414DCBC05AFQ54571803-92EAD004-5CCD-437E-B69A-8024C6E0AEC0Q55040154-F6940C8C-E729-411D-AE93-E489BBC9BF3BQ55215256-8B38006C-17D3-432E-B702-F824BA1E336D
P2860
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Cyclosporine A or intravenous ...... ritis: the Cyclofa-Lune study.
@en
type
label
Cyclosporine A or intravenous ...... ritis: the Cyclofa-Lune study.
@en
prefLabel
Cyclosporine A or intravenous ...... ritis: the Cyclofa-Lune study.
@en
P2093
P2860
P50
P356
P1433
P1476
Cyclosporine A or intravenous ...... ritis: the Cyclofa-Lune study.
@en
P2093
J Rovensky
J Zadrazil
Ss Pesickova
P2860
P304
P356
10.1177/0961203310371155
P577
2010-07-06T00:00:00Z